Vaccitech Raises $168M in Series B Financing

18 Mar, 2021

Vaccitech Raises $168M in Series B Financing
Photo by myHQ Workspaces on Unsplash

– Vaccitech Ltd from Oxford develops a proprietary platform to treat and prevent infectious diseases and cancer.
– The company raised $168m in Series B funding.
– The round was led by M&G Investment Management and attracted new investor Tencent, Gilead Sciences, Monaco Constitutional Reserve Fund, and Future Planet Capital among others.
– The new investment will be used to develop the company’s pipeline of product candidates targeting infectious disease (including MERS coronavirus and Herpes Zoster) and cancer (including non-small cell lung cancer).

Biotechnology Europe Health Care Medical Pharmaceutical Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: